By Rebecca Ryznar, Ph.D., Nerac Associate Analyst
Originally published Sep. 2nd, 2014
Zaire Ebola virus (EBOV), the particular Ebola viral strain currently spreading across West Africa, causes the most virulent hemorrhagic fever known to man, and kills up to 90% of those infected. Ebola sets the immune system in overdrive and perturbs clotting mechanisms, causing a victim to bleed to death within an average of a week after contracting the virus. In the early stages of disease, patients initially present with flu-like symptoms, followed by a hemorrhagic phase associated with vomiting of blood, reddening of the eyes, internal and subcutaneous bleeding, eventually leading to organ failure and death.
- 37Our analyst John Leavitt, Ph.D., was recently featured in an article in USA Today. Take a look at it today! http://www.usatoday.com/story/money/business/2014/11/26/analyst-newlink-deal-boost-ebola-vaccine/19518217/
- 36"Merck wouldn't have done this if there wasn't very good preliminary results from the clinical trials," said Dr. John Leavitt, a senior biotech analyst with the research firm Nerac. "There must be some trial data that is being shared with Merck by NewLink on the progress of these clinical trials." Read the full Des Moines…
- 33By Stephenie Smulligan-Maldanis, M.S., Nerac Analyst, Originally Published: April 19, 2016 Whether we are aware or not, the risks and benefits of pesticide use are part of daily life. As the pesticide market, and the threat of disease continues to grow, so does the concern over the consequences of pesticide use. Increasingly, consumers are skeptical…